The WHO has elevated the importance of addressing Rhesus disease. It has recommended the addition of a point-of-care test, the EldonCard, to determine blood groups and Rhesus factor in the context of maternal health care and haemolytic disease of the fetus and newborn, thereby providing health care professionals with a game changing tool in the fight against Rhesus disease.
Eldon Biologicals expects the listing will have significant positive implications for Rhesus negative mothers across the world, as many governments and international organizations rely of the WHO to guide their use of diagnostics and medications.
Further, with regard to the listing of the EldonCard on the 2023 Essential Diagnostics List, the WHO Strategic Advisory Group of Experts on in vitro diagnostics (SAGE IVD) reviewed 12 applications and recommended the addition of eight IVDs. In response to the application from Eldon Biologicals, the WHO recommends a point-of-care test to determine blood groups and Rhesus factor in the context of maternal health care and haemolytic disease of the fetus and newborn.
There is more information and access to the full report on WHO releases new list of essential diagnostics
